| 前收市價 | 2,221.00 |
| 開市 | 2,228.50 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 2,213.00 - 2,238.50 |
| 52 週波幅 | 2,097.50 - 2,966.50 |
| 成交量 | |
| 平均成交量 | 2,100,459 |
| 市值 | 1.048T |
| Beta 值 (5 年，每月) | 0.17 |
| 市盈率 (最近 12 個月) | 8.38 |
| 每股盈利 (最近 12 個月) | 266.56 |
| 業績公佈日 | 2024年7月31日 |
| 遠期股息及收益率 | 80.00 (3.58%) |
| 除息日 | 2024年9月27日 |
| 1 年預測目標價 | 2,627.00 |
- Reuters
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
Investor's Business DailyDeciphera Catapults 73% On Ono Pharmaceutical's $2.4 Billion Takeover
Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.
- Reuters
UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln
Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States and Europe. Ono Pharma has offered $25.60 per share in cash, a premium of 74.7% to U.S.-based Deciphera's last closing price of $14.65. Some shareholders who own about 28% of Deciphera's outstanding stock have already agreed to tender their shares and support the deal, which is expected to close in the third quarter of 2024, the company said.
